MA50045A - Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci - Google Patents

Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci

Info

Publication number
MA50045A
MA50045A MA050045A MA50045A MA50045A MA 50045 A MA50045 A MA 50045A MA 050045 A MA050045 A MA 050045A MA 50045 A MA50045 A MA 50045A MA 50045 A MA50045 A MA 50045A
Authority
MA
Morocco
Prior art keywords
preparation
methods
same
spirocyclic compounds
spirocyclic
Prior art date
Application number
MA050045A
Other languages
English (en)
Inventor
Daniel J Buzard
Cheryl A Grice
Michael B Shaghafi
Olivia D Weber
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of MA50045A publication Critical patent/MA50045A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050045A 2017-08-29 2018-08-28 Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci MA50045A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762551714P 2017-08-29 2017-08-29

Publications (1)

Publication Number Publication Date
MA50045A true MA50045A (fr) 2020-07-08

Family

ID=65526036

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050045A MA50045A (fr) 2017-08-29 2018-08-28 Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci

Country Status (24)

Country Link
US (1) US11161856B2 (fr)
EP (1) EP3675848B1 (fr)
JP (1) JP7177825B2 (fr)
KR (1) KR20200046053A (fr)
CN (1) CN111032034B (fr)
AU (1) AU2018326497A1 (fr)
BR (1) BR112020003946A2 (fr)
CA (1) CA3072926A1 (fr)
CL (1) CL2020000463A1 (fr)
CO (1) CO2020001715A2 (fr)
CR (1) CR20200088A (fr)
DO (1) DOP2020000040A (fr)
EA (1) EA202090296A1 (fr)
EC (1) ECSP20013332A (fr)
ES (1) ES2914363T3 (fr)
IL (1) IL272578A (fr)
JO (1) JOP20200022A1 (fr)
MA (1) MA50045A (fr)
MX (1) MX2020002254A (fr)
PE (1) PE20200665A1 (fr)
PH (1) PH12020500371A1 (fr)
RU (1) RU2020107039A (fr)
SG (1) SG11202000984YA (fr)
WO (1) WO2019046330A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2793148T3 (es) 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
ES2861648T3 (es) 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3072923A1 (fr) 2017-08-29 2019-03-07 Lundbeck La Jolla Research Center, Inc. Composes spirocycliques et procedes de preparation et d'utilisation de ceux-ci
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
CR20200545A (es) 2018-05-15 2020-12-17 Lundbeck La Jolla Research Center Inc Inhibidores magl
CN111505410B (zh) * 2020-04-02 2022-07-29 矽力杰半导体技术(杭州)有限公司 调光模式检测电路、方法和无调光检测电路及照明系统
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑
GEAP202316332A (en) 2021-01-29 2023-12-11 Cedilla Therapeutics Inc Cdk2 inhibitors and methods of using the same
EP4358954A4 (fr) 2021-06-26 2025-09-03 Cedilla Therapeutics Inc Inhibiteurs de cdk2 et leurs procédés d'utilisation
CA3242372A1 (fr) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibition de la monoacylglycerol lipase (magl)
AU2023264787A1 (en) 2022-05-04 2024-10-31 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
EP4665718A1 (fr) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Petites molécules utilisées en tant qu'inhibiteurs de monoacylglycérol lipase (magl), compositions et utilisation associées

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440803A1 (fr) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulateurs de l'activite du recepteur de la chimiokine
JPWO2008023720A1 (ja) * 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
MX2012004753A (es) 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
AU2011223898A1 (en) 2010-03-04 2012-09-13 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (fr) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Utilisation d'inhibiteurs de PI3K pour le traitement de l'obésité
ES2793148T3 (es) * 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
BR112015004111A2 (pt) 2012-09-25 2017-07-04 Hoffmann La Roche novos derivados bicíclicos
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
CA2979537C (fr) 2015-03-18 2023-08-29 Abide Therapeutics, Inc. Carbamates de piperazine et procedes de preparation et d'utilisation de ceux-ci
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
WO2017087854A1 (fr) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
ES2861648T3 (es) 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3072923A1 (fr) 2017-08-29 2019-03-07 Lundbeck La Jolla Research Center, Inc. Composes spirocycliques et procedes de preparation et d'utilisation de ceux-ci
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso

Also Published As

Publication number Publication date
PE20200665A1 (es) 2020-06-11
CA3072926A1 (fr) 2019-03-07
CR20200088A (es) 2020-04-08
AU2018326497A1 (en) 2020-02-20
JOP20200022A1 (ar) 2020-02-02
US20210214375A1 (en) 2021-07-15
ES2914363T3 (es) 2022-06-09
CN111032034B (zh) 2023-05-02
US11161856B2 (en) 2021-11-02
ECSP20013332A (es) 2020-04-22
BR112020003946A2 (pt) 2020-09-08
CO2020001715A2 (es) 2020-02-28
JP7177825B2 (ja) 2022-11-24
PH12020500371A1 (en) 2020-12-07
SG11202000984YA (en) 2020-03-30
CN111032034A (zh) 2020-04-17
EP3675848B1 (fr) 2022-03-23
DOP2020000040A (es) 2020-08-31
RU2020107039A (ru) 2021-09-30
EP3675848A4 (fr) 2021-03-10
JP2020532547A (ja) 2020-11-12
EA202090296A1 (ru) 2020-08-03
MX2020002254A (es) 2020-07-20
IL272578A (en) 2020-03-31
EP3675848A1 (fr) 2020-07-08
WO2019046330A1 (fr) 2019-03-07
KR20200046053A (ko) 2020-05-06
CL2020000463A1 (es) 2020-07-10

Similar Documents

Publication Publication Date Title
EP3675848A4 (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3370715A4 (fr) Composés chimères de ciblage de protéolyse et procédés de préparation et d'utilisation de ceux-ci
EP3455226A4 (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3504213A4 (fr) Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
EP3504251A4 (fr) Polymères réticulés et procédés de préparation et d'utilisation de ceux-ci
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
MA52492A (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
EP3778607C0 (fr) Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3271352A4 (fr) Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci
EP3504196A4 (fr) Procédés de préparation d'olaparib
EP3645049A4 (fr) Anticorps multispécifiques et procédés de préparation et d'utilisation associés
MA44611A (fr) Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation
MA49560A (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
EP3526205A4 (fr) Composés thérapeutiques et leurs procédés d'utilisation
EP3429754A4 (fr) Cartouches de préparation d'échantillons et leurs procédés d'utilisation
EP3662007A4 (fr) Agents de matité à base de silice et procédés de préparation et d'utilisation desdits agents
EP3349755A4 (fr) Formulations de nicotine, leurs procédés de préparation et d'utilisation
EP3350196A4 (fr) Composés carborane et leurs procédés d'utilisation